As of October 5, 2017, Intuitive Surgical’s (ISRG) forward PE (price-to-earnings) multiple is 120.3x, which is significantly higher than its peers and the industry average.
According to the latest rating recommendations in a Reuters survey comprised of 18 brokerage companies, 61.0% of the firms gave ISRG a “buy” rating, and 33.0% rated it a “hold.”
Intuitive Surgical (ISRG), the leader in minimally invasive robotics surgery, has seen tremendous growth lately. It was trading at its 52-week high of $1,094.55 on October 5, 2017.
BD has a strong product pipeline of innovative products under development in its LifeSciences segment, which includes the company’s diagnostic offerings.
On September 19, 2017, Becton, Dickinson, and Company (BDX), or BD, introduced a new pen needle for its pen injection devices.
BD has a 50-day moving average of $197.25, while its 200-day moving average is $192.35.
Of the 15 firms tracking BD, ~67% of analysts have recommended a “buy” for BD—of which 70% have given a “strong buy” recommendation.
On July 30, 2017, Cardinal Health (CAH) completed the acquisition of Medtronic’s patient recovery business for an all-cash consideration worth $6.1 billion.
In fiscal 2017, Cardinal Health’s (CAH) Medical segment reported robust demand in areas such as surgical kitting, lab services, post acute, and medical services.
Cardinal Health’s (CAH) Specialty Solutions segment provides two types of services: upstream to pharmaceutical and biopharmaceutical manufacturers and downstream to healthcare providers.
Wall Street analysts have projected Cardinal Health’s fiscal 2018 net profit margins to be 1.0%, which will be similar to what the company reported in fiscal 2017.
For fiscal 2018, Cardinal Health (CAH) has projected mid-single-digit revenue growth on a YoY basis, partially driven by the company’s high customer retention rates.
Cardinal Health (CAH) reported revenues of $130.0 billion for fiscal 2017, which is a YoY (year-over-year) rise of 7.0%.
In August 2017, Exelixis (EXEL) submitted an sNDA to the FDA for Cabometyx as a treatment for previously untreated individuals with advanced renal cell carcinoma.
In 2Q17, Exelixis’s (EXEL) Cabometyx generated revenues of ~$80.9 million compared to ~$17.6 million in 2Q16.
In 2Q17, Exelixis (EXEL) generated revenues of ~$99.0 million compared to ~$36.3 million in 2Q16.
Ten analysts were covering Exelixis in October 2017. One analyst suggested a “strong buy,” and five analysts suggested a “buy” rating.
In 2Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenues of ~$83 million, which was ~84% higher YoY and ~12% higher QoQ.
In 2Q17, Alexion Pharmaceuticals’ (ALXN) Soliris generated revenues of ~$814 million, which represented a ~16% YoY rise and a ~4% QoQ rise.
In 2Q17, Alexion Pharmaceuticals (ALXN) generated revenues of ~$912 million, which was ~21% higher YoY (year-over-year) and ~5% higher QoQ.